These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21070569)

  • 41. Simultaneous use of 2 different antimuscarinics to treat refractory urge urinary incontinence. Con.
    Clemens JQ
    J Urol; 2012 Jun; 187(6):1963-5. PubMed ID: 22503026
    [No Abstract]   [Full Text] [Related]  

  • 42. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
    Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
    Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxybutynin in detrusor overactivity.
    Diokno A; Ingber M
    Urol Clin North Am; 2006 Nov; 33(4):439-45, vii. PubMed ID: 17011379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
    Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
    Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.
    Coyne KS; Sexton CC; Thompson C; Bavendam T; Brubaker L
    Int Urogynecol J; 2015 Mar; 26(3):373-82. PubMed ID: 24942375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
    Brubaker L; Chapple C; Coyne KS; Kopp Z
    Urology; 2006 Aug; 68(2 Suppl):3-8. PubMed ID: 16908335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The MATRIX study: evaluating the data in older adults.
    Newman DK
    Director; 2008; 16(2):21-4. PubMed ID: 19343880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overactive bladder.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():8-13. PubMed ID: 21501545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of discontinuing overactive bladder medications.
    Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
    BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 54. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changing treatments for overactive bladder.
    Waine E; Stott M
    Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Has the cost of anti-muscarinic a key role in the success rate of patients diagnosed with overactive bladder syndrome?
    Vecchioli Scaldazza C; Morosetti C; Pace G; Azizi B; Giannubilo W; Ferrara V
    Arch Ital Urol Androl; 2012 Jun; 84(2):68-73. PubMed ID: 22908774
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ
    Urol Nurs; 2010; 30(4):253-4. PubMed ID: 20949812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New drug information: Toviaz.
    Physician Assistants' Prescribing Reference
    JAAPA; 2009 Jun; 22(6):12. PubMed ID: 19601442
    [No Abstract]   [Full Text] [Related]  

  • 60. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.